Mirtazapine Dosing for Chronic Tension-Type Headache Prophylaxis
For prophylaxis of chronic tension-type headache (TTH), start mirtazapine at 30 mg once daily, taken orally in the evening before sleep, and continue for at least 8 weeks to assess efficacy.
Evidence-Based Recommendation
The 2023 VA/DoD Clinical Practice Guideline for headache management does not include mirtazapine in its recommendations for tension-type headache 1. The guideline suggests amitriptyline as the only pharmacologic agent for prevention of chronic TTH (weak recommendation) 1. However, this represents a gap in the guideline, as research evidence supports mirtazapine's efficacy.
Dosing Regimen Based on Research Evidence
Starting Dose and Titration
- Initial dose: 30 mg once daily at bedtime 2, 3
- Alternative starting approach: 15 mg once daily, with potential titration up to 30 mg if needed 4
- Treatment duration: Minimum 8 weeks to adequately assess response 2
The FDA-approved dosing for depression starts at 15 mg with titration up to 45 mg maximum 4, but the specific evidence for chronic TTH prophylaxis used 15-30 mg daily 2.
Key Clinical Trial Data
The highest quality study for TTH prophylaxis showed that mirtazapine 15-30 mg/day reduced the area-under-the-headache curve by 34% compared to placebo (p=0.01) in difficult-to-treat patients with chronic TTH 2. This study demonstrated:
- Reduced headache frequency (p=0.005)
- Reduced headache duration (p=0.03)
- Reduced headache intensity (p=0.03)
- Good tolerability profile
A comparative study found mirtazapine 30 mg daily was as effective as amitriptyline 25 mg for chronic TTH prophylaxis, but with significantly fewer side effects 3.
Important Clinical Considerations
What Does NOT Work
Do not use low-dose mirtazapine (4.5 mg) combined with daily ibuprofen - this combination showed no efficacy and daily ibuprofen actually worsened headache after 3 weeks 5. This is a critical pitfall to avoid.
Practical Implementation
- Timing: Evening administration capitalizes on sedating effects 4
- Dose adjustments: Should not be made more frequently than every 1-2 weeks 4
- Duration of trial: Full 8-week trial needed before declaring treatment failure 2
- Monitoring: Regular assessment of headache frequency, duration, and intensity
Drug Interactions Requiring Dose Adjustment
Per FDA labeling, decrease mirtazapine dose with concomitant use of 4:
- Strong CYP3A4 inhibitors (ketoconazole, clarithromycin)
- Cimetidine
Increase dose may be needed with strong CYP3A inducers (carbamazepine, phenytoin, rifampin) 4.
Common Side Effects
- Sedation/drowsiness (most common)
- Dry mouth
- Weight gain (significant concern - 49% of patients gained ≥7% body weight in pediatric studies) 4
- Generally better tolerated than amitriptyline 3
Contraindications and Warnings
- Screen for bipolar disorder before initiating 4
- Allow 14 days washout when switching to/from MAOIs 4
- Use caution in elderly (40% reduced clearance in males, 10% in females) 4
- Reduce dose in renal impairment (30-50% clearance reduction) 4
- Reduce dose in hepatic impairment (30% clearance reduction) 4
Clinical Context
While amitriptyline remains the guideline-recommended first-line agent for chronic TTH prophylaxis 1, mirtazapine represents a well-studied alternative with comparable efficacy and potentially better tolerability 2, 3, 6. The 30 mg daily dose is supported by the strongest evidence for this indication, though starting at 15 mg with titration is a reasonable approach based on FDA dosing guidance and individual tolerability 4, 2.